UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/530,598	11/12/2005	Moti Harel	E1975-00020	6923
8933 DUANE MOR	7590 09/20/2007 RIS_LLP	EXAMINER		
IP DEPARTMI	ENT	HUANG, GIGI GEORGIANA		
30 SOUTH 177 PHILADELPH	IA, PA 19103-4196		ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			09/20/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

·		Application No.	Applicant(s)				
Office Action Summary		10/530,598	HAREL ET AL.				
		Examiner	Art Unit				
		GiGi Huang	1618				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS,							
WHIC - Exter after - If NO - Failu Any (	CHEVER IS LONGER, FROM THE MAILING DA nations of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN B6(a). In no event, however, may rill apply and will expire SIX (6) M cause the application to become	NICATION. a reply be timely filed  ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
Status	•						
1.) 🖂	Responsive to communication(s) filed on <u>12 November 2005</u> .						
2a) <u></u> □	This action is <b>FINAL</b> . 2b) ☐ This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under E	x parte Quayle, 1935 C	.D. 11, 453 O.G. 213.				
Dispositi	on of Claims	•					
4)🖂	4)⊠ Claim(s) <u>35-64</u> is/are pending in the application.						
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)□	6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)🖾	8) Claim(s) 35-64 are subject to restriction and/or election requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
			•				
Attachment(s)							
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Paper No(s)/Mail Date. 20070907							
3) Inform	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date		f Informal Patent Application				

## **DETAILED ACTION**

The previous restriction has been vacated due to typographical error. The following restriction is corrected and states as follows:

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 35-56, drawn to a composition comprising a carotenoid and a phospholipid.

Group II, claims 57-59 are drawn to a method of feeding an animal a composition comprising a carotenoid and a phospholipid.

Group III, claims 60-64, drawn to a method of preparing an animal feed composition comprising a carotenoid and a phospholipid.

2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Groups I – III is a composition comprising a carotenoid and a phospholipid.

Application/Control Number: 10/530,598

Art Unit: 1618

Bombardelli et al. (U.S. Pat. # 5,897,866) et al. teaches the process of extraction of lycopene and other lipophilic extracts in fruits with phospholipids and several compositions containing lycopene (a carotenoid) and lecithin (a phospholipid).

Therefore, the technical feature linking the inventions of Groups I – III does not constitute a special technical feature as defined by PCT Rule 13.2 lacks novelty as it does not define a contribution over the prior art.

Accordingly, Groups I – III are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

a. Carotenoids: astaxanthin, zeaxanthin, canthaxanthin, lutein, beta-carotene, and lycopene.

Applicant is to elect a species and indicate the source of the elected carotenoid.

The compounds in a Markush group should have a common core and a common utility. The species disclosed in the Markush group contains many species of carotenoids several of which have multiple uses and with very different functions and effects. As a result, the Markush group fails to show common utility.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims

Application/Control Number: 10/530,598

Art Unit: 1618

subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: for Group I - Claim 35, for Group II - Claim 57, for Group III - Claim 60.

b. Phospholipids: at least 20% of the fatty acid residues are polyunsaturated, at least 10% of the fatty acid residues have 3 or more double bonds, at least 10% of the fatty acid residues have 4 or more double bonds, at least 20% of the fatty acid residues have 4 or more double bonds.

Applicant is to elect a species and indicate the specific compound with name and structure of the elected phospholipids. Examples are found in paragraph 56, such as lecithin.

The compounds in a Markush group should have a common core and a common utility. The species disclosed in the Markush group contains many species of phospholipids several of which have multiple uses on commercial and cellular levels; very different functions and effects based on the number of double bonds are present. As a result, the Markush group fails to show common utility.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: for Group I - Claim 35, for Group II - Claim 57, for Group III - Claim 60.

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species and invention to be examined even thought the requirement can be traversed (37 CFR 10143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1618

Should the applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 5. Please note that an election of a group and the species for examination may still be subject to an additional restriction in the future.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to GiGi Huang whose telephone number is (571) 272-9073. The examiner can normally be reached on Monday-Friday 7:30AM-5:00PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecelia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

GH

ZOHREH FAY PRIMARY EXAMMER GROUP 1200

handalika kanalisah minumban berasa

Zohnfron